PharmaVentures advises IDT Australia on the divestment of CMAX clinical trial business to the Japanese company I'rom Group Co. Ltd.

OXFORD, UK, October 28th, 2016

PharmaVentures is pleased to announce that it acted as adviser to IDT Australia Limited for the successful divestment of CMAX, a dedicated clinical trials business, to the Japanese healthcare company I'rom Group Co. Ltd. for a minimum AUD 14,000,000. 

PharmaVentures advises the Baylor Scott & White Research Institute on collaboration with Abzena plc and creation of Denceptor Therapeutics

OXFORD, UK, July 27st, 2016

PharmaVentures is pleased to announce that it acted as an adviser to the Baylor Scott & White Research Institute in connection with the creation of Denceptor Therapeutics Limited.

PharmaVentures expands corporate advisory services through new UK Financial Conduct Authority (FCA) regulated firm

OXFORD, UK, July 21st, 2016

PharmaVentures is pleased to announce that today it has launched a new FCA regulated firm, Pharmaventures Capital Ltd which will carry out all future FCA regulated corporate finance related mandates.

The new firm, which is 100% owned by PharmaVentures, will be able to expand our client offering to include: publice transactions; certain transactions involving listed companies; and fund raising. 

PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today

OXFORD, UK, March 22nd, 2016

PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert adviser to 3Legs on its Reverse Takeover of SalvaRx. 3Legs Resources is an investment company that focuses on life sciences and related technologies. (To read the admission document, download the PDF)

PharmaVentures advises Transgene on the sale of their biopharmaceutical manufacturing facility

OXFORD, UK, February 4th, 2016

PharmaVentures is pleased to announce that it acted as an advisor to Transgene on the sale of its biopharmaceutical manufacturing unit in Strasbourg, France, to the US company Advanced Bioscience Laboratories (ABL), Inc.

Transgene (Euronext: TNG), a member of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases.

PharmaVentures advises Stericool on sale to Sweden’s Getinge Group

Oxford, UK, 17th December, 2015:

PharmaVentures is pleased to announce that it acted as advisor to Stericool on its sale to Sweden’s Getinge Group, a global leader in infection control and contamination prevention solutions.

MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering

Oxford, UK, 16th September, 2015:

PharmaVentures is pleased to announce that it provided transaction support to NovioGendix in its sale to MDxHealth SA (Euronext: MDXH.BR).

PharmaVentures' Latest Deal: Douglas Pharmaceuticals acquires Vital Foods' Phloe product line in New Zealand

OXFORD, UK, September 4th, 2015

PharmaVentures is pleased to announce that it acted as advisor to Douglas Pharmaceuticals, New Zealand's largest pharmaceutical manufacturer, in acquiring from Auckland-based Vital Foods their Phloe® product line in New Zealand for an undisclosed sum. The deal, completed on 1st September, includes an option for additional territories.

PharmaVentures Completes M&A Deal for Technology in the Stem Cell and Regenerative Medicine Sector

OXFORD, UK, June 30th, 2015

PharmaVentures is pleased to announce that it has acted as advisor to CM Technology Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMT's world leading capabilities in cellular imaging and analysis.

This transaction is the latest in a series of successful global deals in the life science research tools sector for PharmaVentures' clients.

Another successful pharma divestment by PharmaVentures

OXFORD, UK, May 29th, 2015 Pharma

PharmaVentures is pleased to announce that it has acted as advisor to one of the top US pharmaceutical companies in its divestment of one of its manufacturing facilities to a US contract manufacturer. The divestment, completed in mid-May, has led to the protection of hundreds of jobs.

This divestment follows PharmaVentures continued success in M&A including the executing of multiple divestments for several of the largest pharmaceutical companies in the world.

Pages